| scholarly article | Q13442814 |
| P50 | author | Edward J Bilsky | Q42452409 |
| Castigliano M Bhamidipati | Q95936058 | ||
| P2093 | author name string | Danxin Wang | |
| Wolfgang Sadée | |||
| John J Lowery | |||
| Kirsten M Raehal | |||
| Jennifer R Blair | |||
| Ryan M Paolino | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | naltrexone | Q409587 |
| opioid | Q427523 | ||
| P304 | page(s) | 1150-1162 | |
| P577 | publication date | 2005-02-16 | |
| P1433 | published in | Journal of Pharmacology and Experimental Therapeutics | Q1500272 |
| P1476 | title | In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice | |
| P478 | volume | 313 |
| Q36090988 | 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists |
| Q34957285 | Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2 |
| Q95320229 | Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network |
| Q36015414 | Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists |
| Q36939998 | Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics |
| Q34980268 | Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating P65 and TRAF6. |
| Q33765435 | Chronic oral or intraarticular administration of docosahexaenoic acid reduces nociception and knee edema and improves functional outcomes in a mouse model of Complete Freund's Adjuvant-induced knee arthritis |
| Q81306022 | Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys |
| Q34441322 | Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice |
| Q39359627 | Constitutive Desensitization of Opioid Receptors in Peripheral Sensory Neurons |
| Q33558914 | Constitutive activation of kappa opioid receptors at ventral tegmental area inhibitory synapses following acute stress |
| Q39220347 | Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence |
| Q44349419 | Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice |
| Q38250226 | Endogenous analgesia, dependence, and latent pain sensitization |
| Q36178615 | Endogenous opioids inhibit early-stage pancreatic pain in a mouse model of pancreatic cancer |
| Q34478755 | Essential role of toll-like receptor 2 in morphine-induced microglia activation in mice |
| Q33651029 | Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor |
| Q34702263 | In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice |
| Q33767106 | In vivo characterization of the opioid antagonist nalmefene in mice |
| Q36666682 | In vivo evaluation of a transdermal codrug of 6-beta-naltrexol linked to hydroxybupropion in hairless guinea pigs |
| Q36054309 | In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay |
| Q24645054 | Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence |
| Q34285100 | Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity |
| Q58798205 | Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity |
| Q36259485 | Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats |
| Q44336809 | Morphine withdrawal enhances constitutive μ-opioid receptor activity in the ventral tegmental area. |
| Q48625496 | Naloxone increases maturation rate and ratio of inner cell mass to total cells in blastocysts in pigs. |
| Q39883445 | Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor |
| Q37781805 | Opioid formulations designed to resist/deter abuse |
| Q35125148 | Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans |
| Q92110581 | Potential uses of naltrexone in emergency department patients with opioid use disorder |
| Q37062561 | Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice |
| Q37121070 | Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist |
| Q38631467 | Repeated administration of mazindol reduces spontaneous pain-related behaviors without modifying bone density and microarchitecture in a mouse model of complete Freund's adjuvant-induced knee arthritis. |
| Q50596818 | Reply to Wang and Sadée. |
| Q28298981 | Role of active metabolites in the use of opioids |
| Q39860832 | Shadows across mu-Star? Constitutively active mu-opioid receptors revisited |
| Q24671847 | Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists |
| Q37387211 | Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. |
| Q42090559 | The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours |
| Q24647249 | The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity |
| Q35165171 | The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice |
| Q36638633 | The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability |
| Q38187259 | The vital role of constitutive GPCR activity in the mesolimbic dopamine system |
Search more.